<bill session="116" type="h" number="3379" updated="2022-11-01T13:51:00Z">
  <state datetime="2019-06-20">REFERRED</state>
  <status>
    <introduced datetime="2019-06-20"/>
  </status>
  <introduced datetime="2019-06-20"/>
  <titles>
    <title type="display">PRICED Act</title>
    <title type="official" as="introduced">To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 5 years.</title>
    <title type="short" as="introduced">Price Relief, Innovation, and Competition for Essential Drugs Act</title>
    <title type="short" as="introduced">PRICED Act</title>
  </titles>
  <sponsor bioguide_id="S001145"/>
  <cosponsors>
    <cosponsor bioguide_id="C001080" joined="2019-07-12"/>
    <cosponsor bioguide_id="C001084" joined="2019-06-20"/>
    <cosponsor bioguide_id="C001119" joined="2019-06-20"/>
    <cosponsor bioguide_id="D000216" joined="2019-06-20"/>
    <cosponsor bioguide_id="D000399" joined="2019-06-20"/>
    <cosponsor bioguide_id="G000586" joined="2019-06-20"/>
    <cosponsor bioguide_id="J000298" joined="2019-06-20"/>
    <cosponsor bioguide_id="K000009" joined="2019-06-20"/>
    <cosponsor bioguide_id="K000389" joined="2019-06-20"/>
    <cosponsor bioguide_id="K000391" joined="2019-06-20"/>
    <cosponsor bioguide_id="L000551" joined="2019-07-12"/>
    <cosponsor bioguide_id="L000592" joined="2019-06-20"/>
    <cosponsor bioguide_id="M001188" joined="2019-10-11"/>
    <cosponsor bioguide_id="M001206" joined="2019-06-20"/>
    <cosponsor bioguide_id="N000147" joined="2019-10-11"/>
    <cosponsor bioguide_id="O000172" joined="2019-06-25"/>
    <cosponsor bioguide_id="P000607" joined="2019-06-20"/>
    <cosponsor bioguide_id="R000606" joined="2019-10-11"/>
    <cosponsor bioguide_id="R000515" joined="2019-06-20"/>
    <cosponsor bioguide_id="T000481" joined="2019-06-20"/>
    <cosponsor bioguide_id="W000800" joined="2019-06-20"/>
    <cosponsor bioguide_id="W000821" joined="2019-06-20"/>
  </cosponsors>
  <actions>
    <action datetime="2019-06-20">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-06-20" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2019-06-21">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="s" number="4796" relation="unknown"/>
    <bill session="116" type="h" number="8527" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Licensing and registrations"/>
    <term name="Marketing and advertising"/>
  </subjects>
  <amendments/>
  <summary date="2020-01-25T18:55:48Z" status="Introduced in House">Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.

This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.</summary>
</bill>
